Unichem Laboratories Limited UNICHEMLAB NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.unichemlabs.com

Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in India, the United States, and internationally. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, bulk drugs, and chemicals. It serves patients, distributors, health care professionals, and government institutions. The company was founded in 1944 and is based in Mumbai, India. Unichem Laboratories Limited is a subsidiary of Ipca Laboratories Limited.

Market & Price

Market Cap

₹2,459.63 Cr

Current Price

₹349.35

High / Low (52W)

₹647.55 / ₹284.05

Beta

Valuation

Stock P/E

9.75

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹346.08

Price to Book

1.01

P/S

1.09

EV/EBITDA

10.78

Dividend Yield

Profitability & Returns

ROCE

11.36%

ROE

9.78%

ROA

2.09%

Profit Margin

11.16%

Op Margin

2.97%

EPS (Latest Qtr)

₹1.55

EPS (TTM)

₹35.84

Balance Sheet & Liquidity

Debt/Equity

0.18

Quick Ratio

1.27

Current Ratio

2.48

Debt

₹500.15 Cr

Total Assets

₹3,737.44 Cr

Current Assets

₹2,197.34 Cr

Working Capital

₹1,311.40 Cr

Ownership

Promoter Holding

71.29%

Chg in Prom Hold

FII / Inst Holding

9.84%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹2,664.42 Cr

Total Revenue (TTM)

₹2,264.91 Cr

EBITDA

₹247.23 Cr

Free Cash Flow

₹-68.50 Cr

Operating Cash Flow

₹3.64 Cr

Shares Outstanding

₹7.04 Cr

Gross Margin

54.94%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

19.13%

Profit 5Y

75.01%

Revenue (YoY)

-2.10%

Earnings (YoY)

-79.30%

PROS

Compounding revenue at 19.1% over 5 years.
Profit CAGR of 75.0% over 5 years.

CONS

Trading 46.0% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	UNICHEMLAB Unichem Laboratories Limited NSEPHARMA	349.35	9.75	₹2,459.63 Cr	-	11.36%	9.78%	19.13%	75.01%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	533.09 Cr	587.18 Cr	526.60 Cr	578.96 Cr	521.17 Cr	575.12 Cr
Cost of Revenue	-	191.52 Cr	264.57 Cr	245.05 Cr	270.38 Cr	237.10 Cr	268.02 Cr
Gross Profit	-	341.57 Cr	322.61 Cr	281.55 Cr	308.58 Cr	284.07 Cr	307.10 Cr
Operating Expenses	-	286.59 Cr	268.60 Cr	290.85 Cr	273.87 Cr	270.54 Cr	290.03 Cr
Operating Income	-	54.98 Cr	54.01 Cr	-9.30 Cr	34.71 Cr	13.53 Cr	17.07 Cr
EBITDA	-	99.14 Cr	92.95 Cr	29.31 Cr	28.89 Cr	332.10 Cr	58.79 Cr
Interest Expense	-	6.75 Cr	5.46 Cr	6.54 Cr	8.24 Cr	7.42 Cr	9.39 Cr
Pretax Income	-	61.85 Cr	57.80 Cr	-9.02 Cr	-10.82 Cr	293.43 Cr	18.79 Cr
Tax Provision	-	4.00 Cr	4.83 Cr	1.45 Cr	1.07 Cr	29.14 Cr	7.88 Cr
Net Income	-	57.85 Cr	52.97 Cr	-10.47 Cr	-11.89 Cr	264.29 Cr	10.91 Cr
Diluted EPS	3.49	8.19	7.50	-1.49	-1.69	37.47	1.55

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	1,302.42 Cr	1,737.63 Cr	2,110.97 Cr	2,201.85 Cr
Cost of Revenue	-	673.17 Cr	864.13 Cr	863.64 Cr	1,020.55 Cr
Gross Profit	-	629.25 Cr	873.50 Cr	1,247.33 Cr	1,181.30 Cr
Operating Expenses	-	784.83 Cr	909.78 Cr	1,107.00 Cr	1,122.25 Cr
Operating Income	-	-155.58 Cr	-36.28 Cr	140.33 Cr	59.05 Cr
EBITDA	-	-46.67 Cr	60.35 Cr	300.18 Cr	449.09 Cr
Interest Expense	-	16.25 Cr	22.15 Cr	21.03 Cr	31.59 Cr
Pretax Income	-	-176.36 Cr	-84.96 Cr	154.59 Cr	292.38 Cr
Tax Provision	-	25.86 Cr	8.80 Cr	17.07 Cr	39.54 Cr
Net Income	-	-202.23 Cr	-93.76 Cr	137.52 Cr	252.84 Cr
Diluted EPS	-	-28.72	-13.32	19.47	35.85

Compounded Sales Growth

5 Years:	19.13%
1 Year:	-2.10%

Compounded Profit Growth

5 Years:	75.01%
1 Year:	-79.30%

Stock Price Performance

1 Year:	-42.12%
6 Months:	-23.42%
3 Months:	-2.07%
1 Month:	-6.91%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	3,193.05 Cr	3,274.95 Cr	3,569.40 Cr	3,737.44 Cr
Current Assets	-	1,588.47 Cr	1,743.32 Cr	2,029.47 Cr	2,197.34 Cr
Cash & Equivalents	-	183.75 Cr	154.75 Cr	89.58 Cr	289.48 Cr
Inventory	-	625.23 Cr	736.26 Cr	988.74 Cr	974.97 Cr
Receivables	-	588.62 Cr	642.31 Cr	778.81 Cr	828.58 Cr
Total Liabilities	-	757.74 Cr	836.65 Cr	1,118.81 Cr	1,020.00 Cr
Current Liabilities	-	639.60 Cr	737.60 Cr	991.97 Cr	885.94 Cr
Long Term Debt	-	63.65 Cr	38.22 Cr	60.81 Cr	39.12 Cr
Total Debt	-	314.05 Cr	247.52 Cr	459.77 Cr	500.15 Cr
Total Equity	-	2,435.30 Cr	2,438.30 Cr	2,450.59 Cr	2,717.44 Cr
Shares Outstanding	-	7.04 Cr	7.04 Cr	7.04 Cr	7.04 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	-85.09 Cr	14.00 Cr	-7.02 Cr	3.64 Cr
Investing Cash Flow	-	202.81 Cr	50.40 Cr	-241.23 Cr	192.06 Cr
Financing Cash Flow	-	-81.30 Cr	-106.31 Cr	183.76 Cr	1.86 Cr
Capital Expenditure	-	-44.32 Cr	-22.55 Cr	-137.36 Cr	-123.04 Cr
Free Cash Flow	-	-129.41 Cr	-8.55 Cr	-144.38 Cr	-119.40 Cr
Net Change in Cash	-	36.42 Cr	-41.91 Cr	-64.49 Cr	197.56 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	48.3%	50.3%	59.1%	53.7%
Operating Margin %	-	-11.9%	-2.1%	6.6%	2.7%
Net Margin %	-	-15.5%	-5.4%	6.5%	11.5%
ROE %	-	-8.3%	-3.8%	5.6%	9.3%
ROCE %	-	-6.1%	-1.4%	5.4%	2.1%

Shareholding Pattern

Insiders

71.29%

Institutions

9.84%

Public Float

34.28%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for UNICHEMLAB

No recent headlines available.

UNICHEMLAB · Healthcare